FIELD: medicine.
SUBSTANCE: invention relates to medicine, specifically to oncology, and can be used in the treatment of B-cell malignant diseases or T-cell malignant diseases. Method comprises administering to a patient a composition comprising (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide (MK-8628).
EFFECT: use of the invention makes it possible to treat splenic marginal zone lymphoma and anaplastic large T-cell lymphoma primarily due to the cytotoxic effect of MK-8628 on lymphoma cells, reduce expression of the c-myc oncogene and the transcription factor NFkB.
1 cl, 9 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMBINATIONS FOR TREATING A MALIGNANT TUMOR | 2017 |
|
RU2726367C2 |
| TREATING MALIGNANT TUMOURS USING MODULATORS OF PI3-KINASE ISOFORMS | 2013 |
|
RU2702908C2 |
| REPROGRAMMING OF EFFECTIVE PROTEIN INTERACTIONS FOR EPIGENETIC DEFECTS CORRECTION IN MALIGNANT TUMOUR | 2013 |
|
RU2637441C2 |
| TREATING MALIGNANT TUMORS USING PIZ-KINASE ISOFORM MODULATORS | 2014 |
|
RU2705204C2 |
| METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | 2020 |
|
RU2820673C2 |
| METHODS OF TREATING CANCER USING APILIMOD | 2016 |
|
RU2738934C2 |
| USING ANTI-CD40-ANTIBODIES | 2008 |
|
RU2491095C2 |
| BIVALENT BROMODOMAIN INHIBITORS AND ROUTES OF USE THEREOF | 2016 |
|
RU2742035C2 |
| APPLICATION OF AN EZH2 INHIBITOR IN COMBINATION WITH A BTK INHIBITOR IN PRODUCTION OF A MEDICINAL PRODUCT FOR TREATING A TUMOUR | 2018 |
|
RU2762893C2 |
| NEW QUINAZOLIONIC DERIVATIVES INHIBITING PI3K, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2017 |
|
RU2702904C1 |
